Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Aventis’ Jevtana is notable for its 11-week expedited review, which made it as the speediest approval of 2010.
You may also be interested in...
The Magnitude Matters: GSK Approvals Show How To Use PFS After Other Drugs Show Survival
Submitting an NDA based on progression-free survival when other drugs for the indication have been approved on the basis of overall survival benefits is a risky proposition, but GlaxoSmithKline was confident the magnitude of Mekinist and Tafinlar’s PFS effect in metastatic melanoma would make the findings clinically relevant.
Accelerated Evolution Of Prostate Cancer Therapy Shaped Xtandi Review
Medivation/Astellas’ enzalutamide capped off an extraordinary three-year run in advanced castration-resistant prostate cancer therapy, with three successive NMEs each offering a greater survival advantage than the last. That accelerated evolution of new therapies created a complex context for FDA reviews.
Review Of Reviews: Drug Review Profiles Of 2011
Each month, Pharmaceutical Approvals Monthly analyzes the FDA review process for a recent approval based on the NDA or BLA review documents. A detailed chronology of product development and listing of key reviewers accompany each profile.